Khloris Biosciences utilizes induced pluripotent stem cells (iPSCs) to develop immunotherapeutic solutions for the treatment and prevention of cancer and cardiovascular diseases. The company focuses on harnessing the potential of iPSCs for drug discovery, vaccine development, and cell therapies to address critical healthcare challenges.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer and cardiovascular diseases remain leading causes of mortality, necessitating innovative approaches for effective treatment and prevention. Traditional therapeutic strategies often face limitations in efficacy, specificity, and long-term disease management.
Solution
Khloris Biosciences leverages induced pluripotent stem cell (iPSC) technology to develop novel immunotherapies targeting cancer and cardiovascular diseases. By harnessing the unique properties of iPSCs, the company aims to create targeted drug candidates, preventative vaccines, and cell-based therapies. These approaches are designed to stimulate the immune system to recognize and eliminate diseased cells, offering a more precise and potentially curative treatment option. Khloris Biosciences is focused on unlocking the full potential of iPSCs to address critical unmet needs in oncology and cardiology.
Target Audience
Khloris Biosciences targets patients suffering from cancer and cardiovascular diseases, as well as healthcare providers and researchers seeking advanced therapeutic options.
Features
- iPSC-derived cell therapies for targeted cancer treatment
- Vaccine development platform utilizing iPSCs to stimulate anti-tumor immunity
- Drug discovery programs focused on identifying iPSC-derived therapeutic molecules
- Immunomodulatory strategies to enhance the body's natural defenses against disease